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Abstract Urea derivatives are ubiquitously found in many
chemical disciplines. N,N0-substituted ureas may show
different conformational preferences depending on their
substitution pattern. The high energetic barrier for iso-
merization of the cis and trans state poses additional
challenges on computational simulation techniques aiming
at a reproduction of the biological properties of urea
derivatives. Herein, we investigate energetics of urea
conformations and their interconversion using a broad
spectrum of methodologies ranging from data mining, via
quantum chemistry to molecular dynamics simulation and
free energy calculations. We find that the inversion of urea
conformations is inherently slow and beyond the time scale
of typical simulation protocols. Therefore, extra care needs
to be taken by computational chemists to work with
appropriate model systems. We find that both knowledge-
driven approaches as well as physics-based methods may
guide molecular modelers towards accurate starting struc-
tures for expensive calculations to ensure that conforma-
tions of urea derivatives are modeled as adequately as
possible.
Keywords Cis/trans isomerization  Starting structure 
Matched molecular pairs  Thermodynamic integration 
Umbrella sampling  Potential of mean force  Drug
design  Molecular modeling  Urea
Introduction
Urea derivatives are broadly used in various disciplines of
chemistry including catalysis, metal binding and
supramolecular chemistry [1]. Furthermore, urea substruc-
tures are prominent in drug design and medicinal chemistry,
where they are introduced to allow strong hydrogen bond-
ing [2] which might lead to cooperative effects [3]. Addi-
tionally, many bioisosteres for urea have been developed
and were successfully applied in structure-based design
campaigns [4]. Drugbank (version 4.3 [5]) lists 148 acyclic
urea-derived compounds among approved and investiga-
tional drugs including prominent examples like ritonavir,
sorafenib, or regorafenib. The bioactivity database
ChEMBL (version 20 [6]) lists 76,494 urea-derived bio-
logically active molecules, thus corresponding to more than
5 % of indexed molecules in total. Thereof, 34,232 N,N0-di-
substituted and 39,426 tri-substituted ureas form the major
contributors (see Fig. 1a). Interestingly, terminal urea
groups are rarely found contributing only 2092 as mono-
substituted ureas and 743 compounds as N,N-di-substituted
ureas in addition to the parent compound urea itself. No
tetra-substituted ureas are listed in ChEMBL at all.
These compounds are distributed over all major target
classes in ChEMBL (see Fig. 1b). Aryl-urea substructures
are for example used to target the inactive DFG-out con-
formation in type II kinase inhibitors [7]. Such compounds
allow unique specificity profiles amongst kinases since a
hydrophobic region apart from the conserved ATP pocket
is targeted [8]. Matched molecular pairs, compounds dif-
fering in a single chemical modification [9], amongst urea-
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derived compounds vary in binding potency over several
orders of magnitude up to six log units (see Fig. 1c, d).
Additionally, double transformation cycles extracted as
cycles of four matched pairs [10] indicate non-additivity of
substituent contributions to binding free energy. These
non-additive contributions to binding free energy likely
arise due to changes in ligand conformation and/or binding
pose (see Fig. 1e for an example).
Computational strategies to estimate differences in free
energy of binding to biological receptors are emerging as
key tools in rational drug design [12]. Though force field
inadequacies and limited sampling times inherently limit
accuracy, free energy calculations provide a valuable
source of directions for lead optimization [13]. Special care
needs to be taken to accurately represent the system in
computationally demanding free energy calculations both
on receptor and ligand side [14, 15].
Urea derivatives pose additional challenges on the
computational chemist, since the planar systems may adopt
different conformations. In general, the trans state is pre-
ferred for ureas, esters and amides [16]. This effect stems
from increased steric repulsion of substituent groups in cis
state [17]. N,N0-diethyl-urea is found in trans/trans con-
formation in apolar media and may give rise to self
assembly via intermolecular hydrogen bonding [18].
Knowledge-driven analysis of torsion profiles from small
molecule crystal structures also revealed a strong prefer-
ence for the trans state over cis with a tolerance of only 20
[19]. The absolute minimum energy conformation of sub-
stituted ureas might in fact deviate slightly from planarity
[20]. Major changes of logD and solubility upon
N-methylation have recently been described for urea
derivatives and been attributed to conformational transi-
tions [21] which appears reasonable since urea-derived
Fig. 1 Bioactivities of urea derivatives: a The vast majority of urea-
derived compounds in ChEMBL is either N,N0-di-substituted (yellow)
or tri-substituted (red). Mono-substituted ureas (green) as well as
N,N-di-substituted ureas (blue) are less frequent. b Urea derivatives
are known to exhibit a variety of bioactivities targeting kinases
(yellow), proteases (orange) and other enzymes (red). Furthermore,
membrane receptors (blue) and ion channels (green) are known
targets as well as further unclassified targets (grey). c, d Affinity
differences (c: IC50 and d: Ki data) derived from matched pairs among
urea derivatives indicate that substitutions of urea compounds may
lead to major changes in binding potency. e An example double
transformation cycle of VEGFR2 inhibitors (with ChEMBL com-
pounds IDs and activity data from [11]): A change in linker
substitution between compounds a and b (para to meta) leads to little
change in binding affinity. Strinkingly, compound a receives a major
affinity boost of 2.5 log units by trifluouromethyl substitution
(compound c). The effect of the identical substitution from compound
b–d shows a much smaller gain in affinity, leading to a non-additivity
of 1.65 log units
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compounds may readily form intramolecular hydrogen
bonds and thereby alter physico-chemical properties [22].
To characterize conformational preferences of urea
substructures we mined the Cambridge Structural Database
(CSD) and extracted conformations for 407 indexed N,N0-
disubstituted ureas with determined three-dimensional
structure. Two torsions per molecule around the urea sub-
structure were analyzed and yielded 814 torsion angles (see
Fig. 2a). 716 of those (88 %) were found to lie within
0 ± 20, representing the dominant planar trans confor-
mation. 1 % of torsions are found between 20 and 30 and
deviate from the trans state slightly. 11 % of urea com-
pounds are found in planar cis conformation
(±180 ± 20), whereas all other ranges of torsion angles
are not populated. 320 structures (79 %) are found in the
trans/trans state with both torsion angles within 0 ± 30.
87 molecules (21 %) are found with one torsion in cis and
one in trans (cis/trans state), whereas not a single molecule
in CSD is found in cis/cis state. Intramolecular hydrogen
bonding is found to trigger conformational changes
between the trans/trans and cis/trans state (see Fig. 2b, c
for an example).
Similar trends were observed when querying the Protein
Data Bank (PDB) [23] for urea derivatives. We retrieved a
manually curated data set of 120 structures, some of which
having multiple ligands bound or multiple conformations
modeled. In agreement with CSD data, the majority of
ligands (93 %) is found in trans/trans conformation,
whereas only few adopt a cis/trans state (see Fig. 3 for
examples). One single structure is even found in cis/cis
conformation. Here, the cis/cis conformation of the urea is
implied both by pocket shape as well as local hydrogen
bonding patterns and can therefore be explained as a result
of ligand strain [27]. Solvent-exposed urea motifs are
predominantely found in trans/trans state, while the
cis/trans state can be readily implied by protein-ligand
interactions. The PDB also contains rare urea conforma-
tions as deposited for urea-linked factor XIa inhibitors
bearing alternative P1 groups [28]. Whether the observed
non-planar substitution pattern (torsion angle: -137.7)
represents reality or an experimental artifact remains
elusive.
The factual absence of structures showing other torsion
angles involving the urea substructure than either the
dominant trans conformation or the minor cis conformation
implies a high energy barrier for the involved torsions.
Herein we investigated whether state-of-the-art simulation
techniques provide a long enough time scale to sample
transitions between those separated energetic minima. We
found that unbiased simulation protocols are insufficient to
sample the involved transitions and therefore extra care
needs to be taken by molecular modelers to appropriately




We used the web interface of ChEMBL to extract com-
pounds with urea substructure from ChEMBL20 [6]. Sub-
sequently, we searched for matched molecular pairs
amongst the urea compounds using the search algorithm of
Hussain and Rea [29] as implemented in RDKit [30].
Presented matched molecular pairs show replacements
directly connected to the urea fragment and fulfill previ-
ously published quality criteria [31]. Ki and IC50 data were
treated separately in the extraction of matched pairs and are
based on the identical source publication and assay
Fig. 2 Urea conformations present in the CSD: a A histogram of
occurring 814 torsion angles in acyclic N,N0-disubstituted ureas
reveals a clear preference for trans states over cis states. b 1-(2-
nitrophenyl)-3-pyridin-3-ylurea (CSD: WOMHUD) shows a planar
trans/trans conformation. c By contrast, 1-(4-fluorophenyl)-3-pyridin-
2-ylurea adopts a cis/trans conformation (CSD: WOMGUC) that is
stabilized via an intramolecular hydrogen bond between urea and
pyridine
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identifier to minimize experimental uncertainty. Creation
of double transformation cycles based on urea-containing
matched pairs was performed as described earlier [10].
We screened the CSD small molecule database (version
5.36, November 2014) using ConQuest 1.17 [32]. We
retrieved structures of acyclic N,N0-di-substituted ureas and
calculated dihedral angles over both sides of the urea
fragment including the substituents’ first atoms. Our search
space was defined as organic molecules with available 3D
structure, no disorder and R-factor B0.05.
Similarly, we used the PDB web interface to search for
N,N0-di-substituted ureas amongst protein-ligand com-
plexes. Since a limitation to acyclic ureas only was
impossible, we performed a manual cleaning step to
remove ligand bearing the urea fragment within a cyclic
substructure. Thereby, the majority of hit structures were
discarded, e.g. due to presence of biotin derivatives.
Molecular structures were visualized using PyMOL (ver-
sion 1.6.0.0, Schrodinger LLC, 2013).
Molecular dynamics simulations
We performed molecular dynamics simulations of N,N0-
dimethyl-urea to investigate kinetic accessibility to cis/-
trans isomerization. Therefore, we parametrized the ligand
using the Generalized Amber Force Field (GAFF) [33] and
AM1-BCC charges [34] as implemented in Amber14 [35].
We followed the suggested work-flow for non-standard
residues in Amber using antechamber for setting of GAFF
atom types and parameter assignment. Planarity was
therefore enforced with a general improper torsion term as
applied for esters or amides.
We investigated three starting conformation: trans/
trans, cis/trans and cis/cis N,N0-dimethyl-urea. Subsequent
to energy minimization, temperature (300 K) and pressure
(1 bar) equilibration, all systems were sampled for 25 ns in
explicit TIP3P water environment [36] using the GPU
implementation of pmemd [37]. Systems were analyzed by
extraction of dihedrals along the SMARTS pattern CNC=O
as well as hydrogen bond counting applying default cut-
offs in cpptraj (maximum heavy atom distance: 3.0 A˚,
minimum angle of interacting atoms: 135) [38].
To enforce transitions between the cis and trans energy
minima we additionally performed umbrella sampling
simulations. Thereby, the dihedral angle over the urea
substructure was slowly biased by a harmonic extra
potential from cis to trans state and vice versa. Simulations
were performed both in solution and vacuum in 121 win-
dows with a shift of 3 in the dihedral minimum. The slope
of the harmonic potential was set to 200 kcal/mol over
180. Each window was sampled over 500 ps and the
resulting distribution was stored in 10,000 snapshots.
Subsequently, the distribution of states was re-weighted
using the weighted histogram analysis method (WHAM)
including dihedral periodicity [39]. Error bars were derived
from ten-fold Monte Carlo random subset sampling.
We performed thermodynamic integration (TI) calcula-
tions to investigate free energy changes in a protein-ligand
system caused by inversion of a urea substructure. There-
fore, we protonated the crystal structure of vascular
endothelial growth factor receptor 2 (VEGFR-2) tyrosine
kinase in complex with a benzamidiazole urea inhibitor
(PDB: 2OH4 [40]) for simulations using protonate3D [41].
The system was parametrized, solvated and energy mini-
mized using the Amber14 package as described above
using Amber ff99SB-ILDN for protein atoms [42]. After an
NpT equilibration over 200 ns we transformed the trifluo-
romethyl group (CF3) close to the ligand’s urea
Fig. 3 Representative urea conformations extracted from the PDB:
Ligands and protein interface residues are shown in stick represen-
tation in elemental colors (carbon: white in proteins, green in ligands),
additionally the protein Van der Waals surface is shown in grey.
Water molecules are shown as red sphere, polar contacts with a
distance smaller than 3.3 A˚ are shown as yellow dashed lines. a The
co-crystal structure of a bacterial urea transporter and N,N0-dimethyl-
urea shows the low energy trans/trans conformation that is stabilized
via hydrogen bonds to a protein backbone carbonyl and to a water
(PDB: 3K3G [24]). b The binding site shape of peptidyl-prolyl cis–
trans isomerase together with the local hydrogen bonding partners
enforce a cis/trans conformation in the urea substructure of a bound
ligand (PDB: 4ZSD [25]). c A substrate analogon shows a rare cis/cis
urea conformation when bound to a bacterial 6-hydroxy-L-nicotine
oxidase (PDB: 3NN6 [26]). d An unlikely non-planar conformation is
represented in the PDB in a co-crystal structure of factor XIa and a
urea-based inhibitor (PDB: 4X6M [28])
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substructure (a topology similar to regorafenib) to a thio-
trifluoromethyl group (SCF3) using a one step TI approach
using soft-core potentials [43]. The transformation was
conducted using 22 k-windows with 1 ns sampling time
each. Error bars for free energies were extracted from ten-
fold trajectory splitting. The template ligand (CF3) was
simulated in trans/trans configuration whereas the target
ligand (SCF3) was simulated in both trans/trans and cis/-
trans configuration. To generate the starting structure the
torsion angle over the terminal aromatic ring was adjusted
manually to cis/trans state (see Supporting figure 1 for
graphical representations). Additionally, we performed a
simulation of the inversion of the template ligand (CF3) in
solution from trans/trans to cis/trans and vice versa.
Quantum mechanical calculations
We conducted dihedral scans at HF/6-311G level for three
compounds using Gaussian03 [44]. First we re-examined
the torsion of N,N0-dimethyl-urea at quantum mechanical
level and added a cyclophilin D ligand (1-(4-aminobenzyl)-
3-[(2S)-4-(methylsulfanyl)-1-{(2R)-2-[2-(methylsul-
fanyl)phenyl]pyrrolidin-1-yl}-1-oxobutan-2-yl]urea, PDB
ligand ID: 7I6) along with the VEGFR-2 ligand used for TI
calculations as real life examples. Rotational scans were
performed on the dihedral angle over the CNC=O
SMARTS pattern which was increased in 5 and 10 steps
respectively from 0 (trans state) to 180 (cis state). For
ligand 7I6 the torsion profile for the 4-amino-benzyl sub-
stituted amide nitrogen was recorded, for the VEGFR-2
ligand we profiled the torsion for the 3-trifluoromethyl-
phenyl amide nitrogen. N,N0-dimethyl-urea was scanned
twice, with and without a constraint enforcing a planar
conformation of the nitrogen amides in order to bypass
potential changes in hybridization state. To counteract
hysteresis effects from the torsion scan, we subsequently
energy minimized identified minimum and transition state
structures for the N,N0-dimethyl-urea system. Additionally,
we performed a torsion scan for all three systems using the
GAFF parameters derived for molecular dynamics
simulations.
Results
We performed molecular dynamics simulations of N,N0-
dimethyl-urea in three conformational states (trans/trans,
cis/trans, cis/cis). We did not observe a single conforma-
tional transition from cis to trans or vice versa over a
sampling time of 25 ns in explicit solvation. To enforce the
inversion of the urea conformation we added biasing
potentials to our simulations by performing an umbrella
sampling. Simulations were performed in vacuum as well
as explicit solvation and both lead to similar free energy
profiles (see Fig. 4). The trans state is identified as global
energy minimum, whilst the cis state is a local energy
minimum with an intrinsic strain energy of 4.1 kcal/mol in
vacuum and 5.7 kcal/mol in explicit solvation. Error bars
from simulations are found well below 0.1 kcal/mol and
strengthen confidence in the presented free energy profiles.
The barrier height for inversion from the trans to cis state is
found as high as 14.0 kcal/mol in vacuum and 14.8 kcal/-
mol in solution.
Since both energy differences from trans state to cis
state as well as to the transition state are elevated in
solution compared to the simulations in vacuum, the trans
state appears additionally stabilized by surrounding water
molecules. We therefore analyzed hydrogen bonding pat-
terns of the three different urea conformations occurring in
the 25 ns long unbiased simulations. We found that trans/
trans N,N0-dimethyl-urea shows the strongest hydrogen
bonding network with surrounding water molecules.
Thereby, the carbonyl function on average forms 1.69
hydrogen bonds, whereas the amide nitrogens donate 0.88
hydrogen bonds to the solvation shell (total 2.57). Inversion
of one bond torsion to the cis/trans state reduces hydrogen
bonds to 1.60 for the carbonyl and 0.57 for the amide
nitrogens (total 2.17). A slight increase in hydrogen bonds
is observed for the cis/cis state of N,N0-dimethyl-urea,
where on average 1.51 hydrogen bonds are formed from
the carbonyl and 0.72 from the amide nitrogens (total
2.22). Therefore, the trans/trans state appears stabilized in
comparison to other conformations not only by its internal
conformational energy but also via gains in hydrogen
bonding to the solvation shells.
To assess the accuracy of force field-based molecular
mechanics based simulations, we performed dihedral scans
of N,N0-dimethyl-urea, cyclophilin D ligand 7I6 and a
VEGFR-2 ligand at HF/6-311G level and compared them
to GAFF energies (see Fig. 5). We found similar energy
profiles for torsional modifications as extracted from sim-
ulation data. Within the constrained dihedral scan the
lowest energy for N,N0-dimethyl-urea was found for a
slightly non-planar conformation at 10. The cis state is
identified as local minimum with an energy difference of
?3.7 kcal/mol. The barrier height between both states is
found to be 16.8 kcal/mol at 110. If no constraint is used,
a hysteresis effect is observed in the energy profile until the
planarity of the urea fragment is re-established at 130
subsequent to a drop in energy. The energy barrier crossed
at 120 is found to be 15.9 kcal/mol and the energy dif-
ference of trans and cis state is significantly lower com-
pared to the constrained scan (?1.1 kcal/mol). Energy
minimizations were performed for lowest energy structures
from torsion scans and resulted in a minimum for the trans
state at 9 compared to 159 for the cis state. The observed
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Fig. 4 Umbrella sampling simulations on N,N0-dimethyl-urea: a State
distributions gathered from umbrella sampling simulation in vacuum
shown as a histogram with 10 bin width. b Reconstructed free energy
profile for the urea inversion from the umbrella sampling in vacuum.
The trans configuration (0) is the global energyminimum,while the cis
state (±180) is only a local minimum with an energy offset of
DDGVacuum = 4.1 kcal/mol. The transitions state is observed at ±82
and a relative energy of DDGVacuum = 14.0 kcal/mol. c State
distributions extracted from umbrella sampling in explicit solvation.
dThe reconstructed free energy profile in explicit solvation is similar to
the corresponding profile in vacuum. Shifts in energy differences in
comparison to the simulations in vacuum are observed between cis and
trans state (DDGSolvation = 5.7 kcal/mol) as well as between trans state
and transition state (DDGSolvation = 14.8 kcal/mol). Additionally, the
transition state is shifted to ±98 in explicit solvation
Fig. 5 Torsional scans at HF/6-311G level and using GAFF: a The
torsion angle around the O=CNC SMARTS pattern in N,N0-dimethyl-
urea was varied from trans state (0) to cis state (180) without further
constraints (black) and enforcing a planar amide conformation (red).
The energy minimum is observed around 10 and is thus slightly non-
planar when enforcing amide planarity, whilst the cis state (180) is
found at 3.7 kcal/mol elevated energy. The energy barrier between
both states is identified at 110 and 16.8 kcal/mol. An unconstrained
scan leads to a lower energy for the cis state but a similar barrier
height. GAFF is found to reproduce the quantum mechanics-derived
energy profile very well (green). b Varying the same torsion angle in
the urea substructure of ligand 7I6 leads to a similar torsion profile
(black). The global energy minimum is found in trans state whilst the
cis state is a local energy minimum with an energy offset of ?1.7
kcal/mol at 170. The barrier between both states is found at 120 and
16.2 kcal/mol. The energy profile derived from GAFF (red) shows
major disagreement with quantum mechanics since a conformational
change in the ligand is observed at the beginning of the scan. c Energy
profile for the torsion scan of the VEGFR-2 ligand: We find an
energetic barrier of 14.5 kcal/mol (100) separating the global energy
minimum in trans state from the cis state (?0.15 kcal/mol). The
GAFF-derived profile (red) shows agreement around the energy
minima but clearly underestimates the barrier height in this case
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energy difference between both states was found to be
1.5 kcal/mol. The barrier was located at 119 and at
15.3 kcal/mol after zero point energy correction. Energy
profiles derived from GAFF showed similar trends as
quantum mechanics-derived profiles. We find the cis state
energetically less favored and to be separated from the
trans state by an energy barrier of 18.8 kcal/mol at 120.
Ligand 7I6, representing a real drug design example,
shows a similar energy profile along the urea torsion as the
model system N,N0-dimethyl-urea. The global minimum is
found in trans state (0), whereas the cis state is
1.7 kcal/mol higher in energy at 170. The energetic barrier
separating both states is found to reach 16.2 kcal/mol at
120 in this case. The VEGFR-2 ligand shows a compa-
rable barrier height and location with 14.5 kcal/mol at
100. Still, we find only little energy difference between
the global minimum at the trans state and the cis state
(?0.15 kcal/mol). For both real world examples we
observe stronger deviations of the GAFF energy profiles
versus the quantum mechanics-derived profiles. Energy
barriers are significantly underestimated and relative
energy levels of cis and trans states are shifted in case of
cyclophilin D ligand 7I6.
We performed TI simulations to investigate free energy
differences between urea conformational states in a pro-
tein-ligand system. Therefore, we kept the template
VEGFR2 ligand in trans/trans configuration as resolved in
the crystal structure and transformed it to the target ligand
in both trans/trans and cis/trans state. We found major
differences in resulting free energy profiles (see Table 1).
A transformation of the co-crystallized CF3-substituted
ligand to the SCF3-substituted target compound yields a
difference free energy of the free energy of binding of
-0.84 kcal/mol when both ligand are simulated in trans/-
trans state (see Supporting Figure 2 for all TI free energy
profiles). Assuming a switch of the target ligand confor-
mation to cis/trans would alter the free energy difference to
?20.81 kcal/mol, thus indicating strong repulsion of the
ligand. The situation is even worse when comparing across
conformational states of the target ligand. Binding free
energy differences of ?80 to ?110 kcal/mol are obtained
when comparing those different states of the ligand. When
inverting the urea conformation of the template ligand
(CF3) in free solution we observe a free energy penalty of
2.80 kcal/mol from trans/trans to cis/trans and
-4.12 kcal/mol for the opposite direction. These values
clearly demonstrate that the trans/trans state is the lowest
energy conformation of our model ligand.
Discussion
In agreement with literature data we have demonstrated
that urea substructures give rise to distinct conformational
states at room temperature. The lowest energy conforma-
tion for most molecules is the trans/trans state. Still, also
alternative conformational states of urea fragments are
thermally accessible and thus need to be considered in high
quality modeling approaches. These higher energy states
are the cis/trans state and the cis/cis conformation, where
the latter state suffers from additional syn repulsion of
methyl groups. Using TI simulations we showed that cal-
culated free energy differences depend drastically on the
ligand setup. Whilst we observe perfect agreement with
experiment when comparing ligands in trans/trans state
(DDGcalculated = -0.84 kcal/mol versus DDGexperiment =
-0.80 kcal/mol [40]), we observe large and thermody-
namically unreasonable deviations of the calculated bind-
ing free energies when assuming a cis/trans state for the
target ligand. Thus, a correct ligand starting conformation
is of utmost importance for the accuracy of TI calculations
although the correct conformational state might not be
immediately obvious in case of urea-derived compounds.
Here, molecular dynamics simulations seeded with an
ensemble of different starting conformations might allow
to identify the conformation most suitable for receptor
binding [45].
The three conformational states of urea derivatives are
separated by high energetic barriers that we estimated in
the range of 14–16 kcal/mol. This finding is in agreement
with experimental data for the solid state, where a barrier
Table 1 Free energy
differences from TI simulations:
depending on the
conformational state of the
target ligand different free
energy differences are
recovered
Template Target Conformation 1 Conformation 2 Environment DG (kcal/mol) Error (kcal/mol)
CF3 SCF3 Trans/trans Trans/trans Solvent 87.93 0.11
CF3 SCF3 Trans/trans Trans/trans Protein 87.09 0.24
CF3 SCF3 Trans/trans Cis/trans Solvent -21.43 0.58
CF3 SCF3 Trans/trans Cis/trans Protein -0.62 3.59
CF3 CF3 Trans/trans Cis/trans Solvent 2.80 0.95
CF3 CF3 Cis/trans Trans/trans Solvent -4.12 0.89
Error bars for predictions increase when the ligand conformation is switched, especially in presence of the
protein
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of 18.5 kcal/mol has been reported [46]. Given the addi-
tional strong hydrogen bonding network in solid state, a
reduction of the barrier height in solution and vacuum has
to be expected. The isomerization of urea fragments in
small molecules is therefore inherently slow with half lives
in the area of milliseconds to seconds. These time scales
are not accessible by state-of-the-art molecular dynamics
simulation approaches that are limited to microsecond
dynamics in proteins [47]. One might therefore consider
urea substructures atropisomers, and thus separate com-
pounds, on the current simulation time scale. Although in
general a rotational barrier of 20–30 kcal/mol is accepted
for real world atropisomerism [48, 49], microsecond
molecular dynamics simulation will typically not allow to
cross barriers of 15 kcal/mol.
Real world atropisomers include well-known biaryls as
well as further chemical classes including N,N0-diarylureas
[50]. Here, it is evident that substitution patterns at the urea
scaffold play a major role in determining lowest energy
conformations as well as barrier height. Aromatic substi-
tution on ureas represent special cases that may give rise to
intramolecular stacking interactions and thereby govern
three-dimensional orientation of substituents [51, 52].
Cis/trans conformational switching of aromatic substituted
ureas has been observed upon simple change of solvent
properties or methylation [53]. Usually, stacked confor-
mations (cis/cis) dominate for simple aromatic ureas as
shown by combination of X-ray crystallography, NMR and
extensive calculations [54]. Interestingly, our analysis of
PDB structures did not reveal a single collapsed di-aryl-
urea structure. Thus, one might speculate that either com-
pounds with this conformational preference are in general
disfavored in protein binding or adopt a structure with
larger accessible surface area upon binding. For accurate
modelling of flexible ligand systems the energetic offset
(ligand strain) between unbound conformation and recep-
tor-bound conformation needs to be included. Sufficient
conformational sampling of the ligand in unbound state can
help to unravel the pre-existing population of the bound
state, and thus its free energy difference, if a mechanism of
conformational selection applies to the studied system [55].
Beyond the class of urea-containing compounds, ben-
zoylureas have been described as removable inducers of cis
amides in the synthesis of cyclic amides as precursors of
macrocycles and peptidomimetics [56]. The cis/trans state
favored in benzoylureas has also been observed in urea-
bearing peptidomimetics in solution [57]. Additionally,
cis/trans isomerization is a crucial parameter in protein
environments, where only 0.03% of amides show a cis
conformation [58] with only a few of them not involving
proline residues [59]. The energy difference between cis
and trans amide is about ?2.8 kcal/mol and brings the need
for extra hydrogen bonding to stabilize the cis
conformation [60]. Prolyl isomerases catalyze the crucial
isomerization step in protein folding that in some cases can
even be rate limiting for the whole folding process [61].
Amide isomerization rates in model peptides have been
shown to reach millisecond to second time scales [62] and
thus will not be accessible with typical simulation
approaches just like inversions of urea conformations.
Modeling therefore requires special attention for correct
system setup not only for the ligand but also for the protein
side whenever internal hindered rotations are involved.
Potential quality issues in starting structures (e.g. urea
conformations strongly deviating from planarity as dis-
cussed earlier) might therefore hamper precise molecular
modeling. Usage of high quality data sets [63] and critical
assessment of starting conformations by experienced
modelers are therefore key to successful predictions.
Additionally, quantum-mechanical calculations as well as
data mining in crystallographic databases might be con-
sidered helpful in identifying limitations in single starting
configurations. In general, urea derived compounds and
similar classes like thioureas, carbamates, thiocarbamates
and amides require special attention for high quality
molecular modeling.
Conclusion
Using a combination of data mining, quantum mechanical
calculations and molecular simulations techniques we
showed that the properties of urea substructures pose sig-
nificant challenges on the molecular modeler. As both
trans/trans and cis/trans conformation appear frequently in
protein-ligand complexes, accurate modeling might require
exploration of both conformers independently since the
energy barrier for inversion is too high to be sampled using
state-of-the-art simulation time scales. An attractive alter-
native could be the application of biasing potentials within
simulations as shown in the presented umbrella sampling
approach to examine the barrier height. We conclude that
extra care needs to be taken by molecular modelers to
accurately describe cis/trans conformational states in urea
fragments and thus to avoid major flaws in sytem ener-
getics. A variety of tools including quantum-mechanical
calculations, knowledge-based approaches as well as
biased simulation techniques might be helpful to face this
additional challenge.
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